Consolidated Statements of Operations and Comprehensive Loss - USD ($)		3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Nov. 16, 2020	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2022	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Operating Costs and Expenses:
General and administrative		$ 2,416,000	$ 1,541,000		$ 3,196,000	$ 5,612,000	$ 9,858,000	$ 6,474,000
Research and development		2,570,000	3,485,000		6,082,000	8,652,000	11,723,000	7,800,000
Total Operating Costs and Expenses		4,986,000	5,026,000		9,278,000	14,264,000	21,581,000	14,274,000
Loss from Operations		(4,986,000)	(5,026,000)		(9,278,000)	(14,264,000)	(21,581,000)	(14,274,000)
Other Income:
Exchange loss		(9,000)	(9,000)		(31,000)	(40,000)	(41,000)	0
Interest income		170,000	26,000		27,000	197,000	512,000	6,000
Total Other Income		161,000	17,000		(4,000)	157,000	471,000	6,000
Net Loss before income taxes		(4,825,000)	(5,009,000)		(9,282,000)	(14,107,000)	(21,110,000)	(14,268,000)
Income tax benefit		335,000	532,000		532,000	867,000	1,425,000	0
Net Loss		(4,490,000)	(4,477,000)		(8,750,000)	(13,240,000)	(19,685,000)	(14,268,000)
Net Loss Attributable to Non-controlling Interest							0	(1,000)
Net Loss Attributable to Theriva Biologics, Inc. and Subsidiaries		(4,490,000)	(4,477,000)	$ (4,273,000)	(8,750,000)	(13,240,000)	(19,685,000)	(14,267,000)
Effect of Warrant exercise price adjustment		$ (340,000)				(340,000)	(340,000)	0
Effect of Series A Preferred Stock price adjustment							0	(7,402,000)
Net Loss Attributable to Common Stockholders			$ (4,477,000)		$ (8,750,000)	$ (13,580,000)	$ (20,025,000)	$ (23,189,000)
Net Loss Per Share - Basic		$ (0.30)	$ (0.28)		$ (0.59)	$ (0.87)	$ (1.31)	$ (1.90)
Net Loss Per Share - Dilutive			$ (0.28)		$ (0.59)	$ (0.87)	$ (1.31)	$ (1.90)
Weighted average number of shares outstanding during the period - Basic		15,844,061	15,844,061		14,837,832	15,176,927	15,327,328	12,187,504
Weighted average number of shares outstanding during the period - Dilutive		15,844,061	15,844,061		14,837,832	15,176,927	15,327,328	12,187,504
Loss on foreign currency translation		$ (1,527,000)	$ (1,497,000)		$ (1,317,000)	$ (2,844,000)	$ (679,000)	$ 0
Total comprehensive loss		(6,017,000)	(5,974,000)		(10,067,000)	(16,084,000)	(20,364,000)	(14,268,000)
Comprehensive loss attributable to non-controlling interest							0	(1,000)
Comprehensive loss attributable to Theriva Biologics, Inc. and Subsidiaries		$ (6,017,000)	$ (5,974,000)		$ (10,067,000)	$ (16,084,000)	$ (20,364,000)	(14,267,000)
Series A Preferred Stock
Other Income:
Preferred Stock Dividends								(24,000)	$ (254,000)
Effect of Series A Preferred Stock price adjustment								(7,402,000)
Series B Preferred Stock
Other Income:
Effect of Warrant exercise price adjustment	$ (880,000,000,000)
Preferred Stock Dividends								$ (1,496,000)